Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer
Publication Year 2015-08,Volume 15,Issue #8,Page 1033-48
Journal Title
Expert Rev Mol Diagn
Publication Type
Journal Article
The role of biomarker assessment in determining the best therapeutic options for patients with metastatic colorectal cancer has become increasingly complex and important. Biomarkers that predict the efficacy and/or toxicity of such treatments can affect medical decision making, leading to decreased harm and/or costs associated with treatment and improvements in therapeutic outcomes for patients. This review discusses traditional and emerging biomarkers of potential clinical utility for patients with metastatic colorectal cancer, current assays and methods used in clinical practice, technologies that have allowed the identification of new biomarkers and key considerations for oncologists and pathologists when determining appropriate biomarker evaluations to be undertaken for their patients.
Taylor & Francis
WEHI Research Division(s)
Systems Biology And Personalised Medicine
PubMed ID
Terms of Use/Rights Notice
Refer to copyright notice on published article.

Creation Date: 2015-09-02 03:35:46
Last Modified: 2015-09-03 03:45:50
An error has occurred. This application may no longer respond until reloaded. Reload 🗙